-
公开(公告)号:US07109238B2
公开(公告)日:2006-09-19
申请号:US10761986
申请日:2004-01-21
申请人: Maria Amparo Lago , James Francis Callahan , Pradip Kumar Bhatnagar , Eric G. Del Mar , William M. Bryan , Joelle L. Burgess
发明人: Maria Amparo Lago , James Francis Callahan , Pradip Kumar Bhatnagar , Eric G. Del Mar , William M. Bryan , Joelle L. Burgess
IPC分类号: A61K31/335 , A61K31/195 , C07C303/08 , C07C63/04 , C07D255/03
CPC分类号: C07D303/22 , C07C33/34 , C07C69/616 , C07C69/738 , C07C211/26 , C07C211/30 , C07C229/36 , C07C233/05 , C07C251/48 , C07C255/57 , C07C255/58 , C07C2602/08
摘要: Novel calcilytic compounds and methods of using them are provided.
-
公开(公告)号:US20100179143A1
公开(公告)日:2010-07-15
申请号:US12602333
申请日:2008-05-29
IPC分类号: A61K31/4375 , C07D471/04 , A61K31/496 , A61K31/5377 , A61P37/06 , A61P29/00 , A61P37/08 , A61P9/00 , A61P11/06 , A61P1/18 , A61P13/12 , A61P17/06 , A61P25/00 , A61P25/28 , A61P9/10 , A61P35/00
CPC分类号: C07D471/04
摘要: Invented is a method of inhibiting the activity/function of PI3 kinases using naphthyridine derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of naphthyridine derivatives.
摘要翻译: 本发明是使用萘啶衍生物抑制PI3激酶的活性/功能的方法。 还发明了一种治疗选自以下的一种或多种疾病状态的方法:自身免疫性疾病,炎性疾病,心血管疾病,神经变性疾病,变态反应,哮喘,胰腺炎,多器官功能衰竭,肾脏疾病,血小板聚集,癌症,精子活力,移植排斥反应, 通过施用萘啶衍生物的移植排斥和肺损伤。
-
公开(公告)号:US07087758B2
公开(公告)日:2006-08-08
申请号:US10474084
申请日:2002-04-04
IPC分类号: A61K31/47 , C07D215/38 , C07D215/12
CPC分类号: C07D401/12 , A61K31/47 , A61K31/4709 , C07D215/54
摘要: This invention relates to novel quinoline inhibitors of hYAK1 and hYAK3 kinases and pharmaceutically acceptable salts, hydrates or solvates thereof, pharmaceutical compositions thereof, and methods of treatment of diseases in which an excessive amount of either such kinase is a factor.
摘要翻译: 本发明涉及hYAK1和hYAK3激酶的新型喹啉抑制剂及其药学上可接受的盐,水合物或溶剂化物,其药物组合物和治疗其中过量的这种激酶是因子的疾病的方法。
-
公开(公告)号:US07482455B2
公开(公告)日:2009-01-27
申请号:US10530986
申请日:2003-10-15
申请人: Joelle L. Burgess , James F. Callahan , Toshihiro Hamajima , Satoru Ida , Ichiro Mori , Jun Tang
发明人: Joelle L. Burgess , James F. Callahan , Toshihiro Hamajima , Satoru Ida , Ichiro Mori , Jun Tang
IPC分类号: C07D215/38
CPC分类号: C07D401/12 , C07D215/54 , C07D405/12
摘要: 3-carboxy quinoline derivatives, which are useful as YAK3 inhibitors are described herein. The described invention also includes methods of making such 3-carboxy quinoline derivatives as well as methods of using the same in the treatment of diseases mediated by inappropriate YAK3 activity.
摘要翻译: 本文描述了可用作YAK3抑制剂的3-羧基喹啉衍生物。 所述的发明还包括制备这种3-羧基喹啉衍生物的方法以及用于治疗由不适当的YAK3活性介导的疾病的方法。
-
公开(公告)号:US06465493B1
公开(公告)日:2002-10-15
申请号:US09958639
申请日:2001-10-09
IPC分类号: A61K3144
CPC分类号: C07D401/04 , C07D405/14 , C07D413/04
摘要: Compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R2 and R3 are various substituent groups; and one of X1 and X2 is N or CR′, and the other is NR′ or CHR′ wherein R′ is hydrogen, OH, C1-6alkyl, or C3-7cycloalkyl; or when one of X1 and X2 is N or CR′ then the other may be S or O; and their use as pharmaceuticals.
摘要翻译: 式(I)化合物或其药学上可接受的盐:其中R1,R2和R3是各种取代基; 且X 1和X 2的一个为N或CR',另一个为NR'或CHR',其中R'为氢,OH,C 1-6烷基或C 3-7环烷基; 或者当X1和X2之一为N或CR'时,另一个可以是S或O;以及它们作为药物的用途。
-
公开(公告)号:US07166639B2
公开(公告)日:2007-01-23
申请号:US10491710
申请日:2002-10-04
申请人: Zehong Wan , Joelle L. Burgess , James F. Callahan
发明人: Zehong Wan , Joelle L. Burgess , James F. Callahan
IPC分类号: A61K31/38 , C07D333/36
CPC分类号: C07D333/36 , C07D333/38
摘要: The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in which diseases excessive activation of NF-κB is implicated.
摘要翻译: 本发明提供了使用它们用IkappaB的IKK-β磷酸化的氨基噻吩抑制剂治疗疾病的新型化合物和方法。 在这样做时,这些氨基噻吩抑制剂阻断转录因子NF-κB的病理活化,其中涉及NF-κB的过度活化。
-
-
-
-
-